On July 1, 2026, the Centers for Medicare and Medicaid Services (CMS) launched the Medicare Bridge demonstration, extending GLP-1 access to certain Medicare beneficiaries.
For manufacturers, Bridge is worth watching for reasons that have little to do with GLP-1 coverage itself. It is a live test of how Medicare and commercial payers will evaluate the next wave of high-cost therapies under the Inflation Reduction Act's (IRA) Part D redesign, which shifted more of the drug spend onto plans.
The questions plans are actually asking are how persistent will patients be on therapy, and when will the downstream medical savings show up in claims? Clinical trial data cannot answer either, thus Bridge was designed to generate the real-world evidence that will.
While the clinical story is settled the economic one still remains: whether broader GLP-1 use lowers long-term spend enough to justify the upfront price, and whether payers capture that value for the patients they cover.
For manufacturers with high-cost therapies in the pipeline the commercial conversation is going to hinge on persistence and the medical offsets that show up, or don't, in real-world data.
CMS initially planned to expand GLP-1 access through a voluntary model called BALANCE, which would have let Medicare Part D plans offer the drugs at discounted prices. Yet, not enough plans were signed on so CMS pivoted to the Bridge demonstration.
The reason plans were held back was financial, because under the Part D restructuring from the IRA plans now carry more of the drug spend themselves. A high-demand category with uncertain persistence and long-tail medical offsets is exactly the kind of exposure actuaries cannot yet size.
That is what Bridge is really about. CMS is letting evidence accumulate before committing Medicare to a permanent coverage decision. Once plans can see how long patients stay on these drugs and when the downstream savings actually land in claims, the coverage question becomes answerable.
Bridge is, in many ways, a national evidence-generation initiative. Over the coming years, stakeholders will need to understand:
These insights will shape not only the future of GLP-1 coverage, but also Medicare's approach to future high-cost therapies.
Manufacturers that can answer these questions early will be better positioned during payer negotiations, evidence generation, and value and market access planning.
Manufacturers need longitudinal visibility that follows patients across therapies, benefit phases, and even payers while capturing their clinical and financial context. Understanding adherence, persistence, benefit progression, payer dynamics, coding practices, and total healthcare utilization provides a far more comprehensive picture of product value to secure payer access. As Medicare continues evolving, these insights will increasingly determine how therapies are evaluated, and ultimately reimbursed.
The Bridge demonstration may be temporary, but the questions it seeks to answer are not. Future payer access decisions will increasingly depend on demonstrating where value occurs, when it occurs, and for whom. Symphony Health, a HealthVerity company, combines comprehensive longitudinal claims with advanced payer analytics to help manufacturers answer those questions.
The Bridge demonstration reflects a broader shift in how payers evaluate innovation. Tomorrow's market access decisions will depend on real-world evidence that connects clinical outcomes with utilization, economics, and patient behavior. Manufacturers that invest in that understanding today will be better prepared to navigate the reimbursement landscape of tomorrow.
See how Symphony Health data can help you navigate the IRA and Part D redesign: https://healthverity.com/symphony-health/making-medicines-more-affordable/